Cirrhosis Secondary to NASH: Causes, Symptoms, and Treatment

Cirrhosis caused by nonalcoholic steatohepatitis (NASH) develops when years of fat-driven liver inflammation slowly replace healthy tissue with scar tissue, eventually distorting the organ’s architecture enough to impair its function. NASH-related cirrhosis has become one of the fastest-growing liver diseases worldwide, with global incidence rates climbing steadily over the past decade while cirrhosis from most other causes has held steady or declined.¹ Understanding how the disease starts, what drives it forward, and what can be done about it matters because NASH cirrhosis is often diagnosed late and carries complications that extend well beyond the liver.

A Quick Note on Names

You may see two sets of terminology floating around. For decades, the condition was called nonalcoholic fatty liver disease (NAFLD) at the early stage and nonalcoholic steatohepatitis (NASH) when inflammation and cell damage set in. In 2023, major liver societies adopted new names: metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The biology is the same; the rename reflects the metabolic roots of the disease and drops the “nonalcoholic” label, which many patients and clinicians found stigmatizing. Most published research still uses NASH and NAFLD, so both sets of terms appear throughout the medical literature. This article uses whichever term a cited study used, but treat NASH and MASH as interchangeable.

How Fatty Liver Becomes Cirrhosis

The road from a fatty liver to cirrhosis is not a single event but a chain of escalating damage. It begins with excess fat accumulating inside liver cells. That fat itself is not necessarily harmful, and many people with simple fatty liver never progress further. The trouble starts when toxic lipid byproducts, particularly certain free fatty acids and cholesterol derivatives, begin poisoning liver cells from the inside. This process, called lipotoxicity, triggers cell death and inflammation.²

At the cellular level, the damage centers on mitochondria, the energy-producing structures inside liver cells. Lipid overload disrupts their normal function, causing them to churn out reactive oxygen species, essentially molecular shrapnel that damages surrounding structures. As liver cells die, they release distress signals that activate the immune system and, critically, switch on a type of cell called a hepatic stellate cell.³ In a healthy liver, stellate cells are quiet and store vitamin A. When activated, they transform into collagen-producing machines, laying down scar tissue throughout the liver.⁴ If the cycle of injury and scarring continues long enough, fibrosis advances through several stages until the liver is so riddled with scar tissue that its internal structure is fundamentally altered. That end stage is cirrhosis.

Who Is Most at Risk

Not everyone with fatty liver develops NASH, and not everyone with NASH develops cirrhosis. Several factors tilt the odds. Among the most powerful is type 2 diabetes. In a large retrospective study, people with fatty liver disease who also had diabetes faced roughly 2.8 times the risk of progressing to decompensated cirrhosis compared to those without diabetes.⁵ That same study found that older age was another strong predictor, with people aged 70 and above carrying nearly five times the risk compared to younger adults. A history of major cardiovascular events also roughly doubled the likelihood of progression.

Obesity is intertwined with all of these risk factors. Excess body fat, especially visceral fat around the organs, drives insulin resistance, which in turn promotes fat deposition in the liver and amplifies the inflammatory cascade. The relationship goes both directions: the liver inflammation itself worsens insulin resistance, creating a feedback loop that is hard to break without significant weight loss.

Genetics play a quieter but real role. A variant in the PNPLA3 gene has received the most attention. People who carry two copies of the risk version of this gene have more than double the rate of severe liver disease over long follow-up compared to those without it.⁶ This gene variant is common in certain populations and likely explains part of why some people with relatively modest metabolic risk factors still develop advanced disease while others with severe obesity do not.

How Common Is It

Among people with fatty liver disease seen in general practice, roughly 3% already have cirrhosis. In hospital and referral settings, where patients tend to be sicker, that number climbs to about 15%.⁷ Those figures might sound small, but given that fatty liver disease affects roughly a quarter of the global adult population, even a low progression rate translates into tens of millions of people. In 2021 alone, MASH-related cirrhosis accounted for over 48 million incident cases globally, and it was the only cause of cirrhosis whose incidence rate was actually rising.¹

Symptoms and the Compensated-Decompensated Divide

One of the trickiest things about NASH cirrhosis is that it can be present for years without causing obvious symptoms. Cirrhosis progresses through two broad phases. In the compensated phase, the liver is scarred but still manages to perform its essential jobs: filtering blood, producing clotting factors, processing nutrients, clearing toxins. People in this phase may feel fine, or they may experience vague fatigue and mild abdominal discomfort that is easy to attribute to other causes.⁸

The shift to decompensated cirrhosis is when the disease becomes unmistakable. Decompensation means the liver can no longer keep up, and complications emerge:

Ascites: Fluid accumulates in the abdomen, sometimes dramatically, causing bloating, weight gain, and difficulty breathing.
Variceal bleeding: Swollen veins in the esophagus or stomach can rupture and cause life-threatening bleeding.
Hepatic encephalopathy: Toxins that the liver normally clears, particularly ammonia, build up in the blood and affect brain function, causing confusion, personality changes, and in severe cases, coma.
Jaundice: Yellowing of the skin and eyes from bilirubin the liver can no longer process.
Susceptibility to infections: The immune dysfunction that accompanies advanced cirrhosis leaves patients vulnerable to bacterial infections, particularly spontaneous bacterial peritonitis, an infection of the fluid in the abdomen.

Decompensation is the dividing line that transforms cirrhosis from a manageable chronic disease into one with high hospitalization rates and significant mortality.

Portal Hypertension, Even Before Cirrhosis

Portal hypertension, or elevated blood pressure in the vein that feeds the liver, is the engine behind most cirrhosis complications. Scar tissue blocks normal blood flow through the liver, forcing pressure to build. The body responds by opening up alternative blood vessels, called collaterals, which bypass the liver. Those collateral vessels are fragile and include the esophageal varices that can bleed catastrophically. Meanwhile, the backed-up pressure pushes fluid out of blood vessels and into the abdominal cavity, producing ascites.⁹

What makes NASH unusual is that portal hypertension can develop before cirrhosis is fully established. Swollen, fat-laden liver cells physically compress the tiny blood channels (sinusoids) inside the liver, increasing resistance to flow even when scarring is still in its early stages. That mechanical compression triggers further dysfunction in the cells lining those channels, setting up a vicious cycle that promotes both higher pressure and more fibrosis.¹⁰ This means some NASH patients experience complications traditionally associated with cirrhosis, like varices, at a stage when their biopsies show only moderate fibrosis.

How NASH Cirrhosis Is Diagnosed

Liver biopsy has long been considered the gold standard for staging liver disease, but it is invasive, uncomfortable, and impractical for screening large populations. Over the past decade, non-invasive methods have become the front line of diagnosis. The two main approaches are blood-based biomarker panels and imaging techniques that measure liver stiffness.¹¹

Ultrasound-based elastography, often called FibroScan, sends a vibration pulse through the liver and measures how quickly it travels. Stiffer tissue (more scar) transmits the wave faster. Magnetic resonance elastography works on the same principle but uses MRI for a more detailed picture. Blood tests like the FIB-4 index combine routine lab values such as age, platelet count, and liver enzymes into a score that helps stratify patients as low, intermediate, or high risk for advanced fibrosis. These tools are not perfect individually, but used in combination they can identify advanced disease with reasonable accuracy, sparing many patients from biopsy.

Weight Loss as Treatment

Weight loss remains the most effective intervention for NASH at every stage, including early cirrhosis. Losing at least 5% of body weight can improve liver fat and inflammation. Reaching 7 to 10% weight loss begins to reverse fibrosis in some patients. And in studies where people achieved 10% or more weight loss, roughly 90% had complete resolution of NASH and nearly half showed measurable improvement in fibrosis.¹² The problem is practical: only about 10% of participants in that study actually hit the 10% threshold. Sustained weight loss of that magnitude is extraordinarily difficult for most people to achieve through diet and exercise alone.

More intensive dietary programs have shown promising results. In a small trial, adults with NASH and fibrosis who followed a very-low-calorie total diet replacement program (around 880 calories per day) for 12 weeks, followed by gradual food reintroduction, lost an average of 15% of their body weight. The vast majority showed significant reductions in liver fat, inflammation markers, and liver stiffness.¹³ This kind of program requires close medical supervision and dietetic support, but it demonstrates that the liver can respond dramatically when the metabolic insult is removed aggressively enough.

No particular diet has proven superior for NASH beyond its ability to produce weight loss. Mediterranean-style eating patterns are frequently recommended because they emphasize foods that benefit metabolic health: vegetables, whole grains, fish, olive oil, and limited processed sugar. But the core message is simpler: calorie reduction that produces meaningful, sustained weight loss is what moves the needle.¹⁴

Drug Treatments

For decades there was no approved medication for NASH. That changed in 2024 with the approval of resmetirom, a drug that activates a specific thyroid hormone receptor concentrated in the liver. By switching on that receptor, resmetirom ramps up the liver’s ability to burn fat and reduces the lipotoxic burden driving inflammation. In a large phase 3 trial, about 26% of patients taking 80 mg and 30% taking 100 mg achieved resolution of NASH without worsening of fibrosis, compared to roughly 10% on placebo. Fibrosis improved by at least one stage in about 24 to 26% of treated patients, versus 14% on placebo.¹⁵ Those numbers may sound modest, but they represent a meaningful shift: for the first time, a drug demonstrated both histological improvement and a plausible path toward slowing progression to cirrhosis. Meta-analyses confirmed significant reductions in liver fat content with both the 80 mg and 100 mg doses.¹⁶

GLP-1 receptor agonists, a class of drugs originally developed for type 2 diabetes and now widely used for weight loss, are generating strong interest as NASH treatments as well. Semaglutide, the best-known member of this class, was tested in a placebo-controlled trial where 59% of patients receiving the highest dose achieved NASH resolution without worsening fibrosis, compared to 17% on placebo.¹⁷ The catch was that fibrosis improvement itself did not reach statistical significance in that trial, possibly because the study was not large enough or long enough to capture it. Still, GLP-1 agonists have an advantage in that they also drive weight loss, improve blood sugar control, and reduce cardiovascular risk, which matters enormously for NASH patients who often die of heart disease rather than liver failure.¹⁸ These drugs are not yet formally approved for NASH, but they are already prescribed off-label for patients who also have obesity or diabetes.¹⁹

Managing Complications Once Cirrhosis Is Established

When cirrhosis is already in place and decompensation occurs, treatment shifts from trying to reverse fibrosis to managing complications and preventing further deterioration. This involves multiple strategies tailored to whichever complications are present. Ascites is managed with salt restriction and diuretics; large-volume fluid removal (paracentesis) is used when the fluid buildup is severe. Hepatic encephalopathy is treated with lactulose and the antibiotic rifaximin, both aimed at reducing ammonia levels. Variceal bleeding is prevented with beta-blockers and treated with endoscopic banding when varices are found. Infections require early, aggressive antibiotic therapy.²⁰

Newer thinking in cirrhosis management is moving beyond treating each complication as a separate problem. Research increasingly focuses on addressing the underlying mechanisms that drive decompensation, including gut bacteria that leak into the bloodstream (bacterial translocation), the disturbed circulation that accompanies advanced liver disease, and the systemic inflammation that accelerates organ dysfunction. Treating the underlying cause of cirrhosis, whether through weight loss, metabolic control, or new drug therapies, remains important even after decompensation, because reducing ongoing liver injury can slow further decline.

Liver Cancer Risk

Cirrhosis from any cause raises the risk of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. In NASH-related cirrhosis, the annual incidence of HCC has been estimated at anywhere from about 2.6% to nearly 13%, a wide range that reflects differences in the populations studied and how closely patients were monitored.²¹ What makes NASH particularly concerning is that a significant proportion of liver cancers in these patients develop even before cirrhosis is established. That complicates screening, because current guidelines generally recommend regular surveillance only for patients with confirmed cirrhosis. People with NASH who have not yet been diagnosed with cirrhosis may fall through the gaps.

The metabolic environment of NASH, chronic inflammation, insulin resistance, and oxidative stress, creates conditions that favor the DNA damage and unchecked cell growth leading to cancer. This is one of the reasons early detection and management of NASH is so critical; by the time cirrhosis is diagnosed, cancer surveillance needs to begin immediately, typically with abdominal ultrasound every six months.

Cardiovascular Disease as the Bigger Killer

It may sound counterintuitive, but for many NASH patients, the greatest threat to life is not the liver but the heart. NASH is fundamentally a metabolic disease, and the same insulin resistance, inflammation, and lipid abnormalities that damage the liver also accelerate atherosclerosis and cardiovascular disease. Studies have consistently found a three- to four-fold increase in the odds of cardiovascular disease among MASH patients compared to those with less advanced fatty liver disease. The risk was elevated for coronary artery disease, stroke, and heart failure, and several studies also showed increased cardiovascular mortality.²² This reality shapes treatment priorities: managing blood pressure, cholesterol, and blood sugar is not secondary to liver care in NASH patients; it is co-equal.

Liver Transplantation

When cirrhosis is too advanced for medical therapy to reverse, liver transplantation remains the definitive treatment. NASH has become one of the leading indications for transplant in many countries, and its share of the transplant waitlist continues to grow. Outcomes after transplant for NASH patients are broadly comparable to other causes of cirrhosis. One large study found five-year survival rates of 85% for NASH patients versus 80% for non-NASH patients, a reassuring equivalence.²³

There are important caveats. NASH transplant recipients have higher early mortality in the weeks following surgery, roughly double that of non-NASH patients, driven largely by infectious complications and cardiac events. Patients with the highest-risk profile, those over 60 with obesity, diabetes, and hypertension, had notably worse outcomes, with five-year survival dropping to about 72% compared to 87% for NASH patients without those features.²³ Another concern specific to NASH is that the metabolic syndrome does not disappear after transplant. Fatty liver can recur in the new organ, and metabolic risk factors often persist or worsen due to immunosuppressive medications that promote weight gain and insulin resistance. Ongoing metabolic management after transplant is essential.

Muscle Loss and Its Overlooked Impact

Sarcopenia, the progressive loss of muscle mass and strength, is a common and underappreciated complication of cirrhosis, and it is especially relevant in NASH. The paradox is that NASH patients are often overweight or obese, so muscle wasting can be hidden beneath excess fat. This “sarcopenic obesity” is easy to miss on casual examination but carries serious consequences. In people with chronic liver disease, sarcopenia independently predicts reduced quality of life, higher complication rates, and increased mortality.²⁴ In patients who develop liver cancer, the presence of sarcopenia is associated with worse survival regardless of tumor stage or treatment.²⁵

The mechanisms behind sarcopenia in cirrhosis include poor nutrient absorption, chronic inflammation, altered hormone levels, and increased ammonia in the blood, which is directly toxic to muscle tissue. For NASH patients, the challenge is preserving or building muscle while also losing fat, since both goals benefit the liver. Resistance exercise and adequate protein intake (adjusted for the level of encephalopathy risk) are currently the main strategies, though research into targeted therapies is ongoing. Recognizing sarcopenia early, ideally through routine body composition assessment, allows clinicians to intervene before the consequences become irreversible.

NASH in Children and Younger Adults

NASH is no longer a disease of middle age. Rising rates of childhood obesity have made fatty liver disease the most common chronic liver condition in children in many countries.²⁶ While cirrhosis in children with NASH is still uncommon, fibrosis has been documented in pediatric liver biopsies, and the concern is what happens over a lifetime. A teenager with early NASH who does not change course has decades of potential liver injury ahead, which could mean cirrhosis in their thirties or forties rather than their sixties. Pediatric NAFLD is also associated with other health problems beyond the liver, including early cardiovascular changes and metabolic syndrome, underscoring that this is a whole-body disease even in its earliest forms. The economic and quality-of-life burden is considerable, and it is projected to grow as the first large generation of children with NASH ages into adulthood.²⁷

The Gut-Liver Connection

The liver receives about 75% of its blood supply from the gut via the portal vein, which means whatever crosses the intestinal barrier goes straight to the liver first. In NASH, the intestinal barrier tends to become “leakier,” allowing bacterial products to reach the liver in higher quantities. These bacterial signals activate immune cells in the liver and amplify the inflammatory response already set in motion by fat toxicity.²⁸ The composition of gut bacteria also shifts in people with NASH, with changes that may promote greater energy extraction from food and increased production of certain metabolites that worsen liver inflammation. Strategies aimed at correcting gut imbalances, through probiotics, dietary fiber, or targeted antibiotics, are being studied but have not yet become standard therapy. It is an active and promising area of research, but for now the practical implication is that overall metabolic health, including a diet rich in fiber and low in ultra-processed foods, likely supports better gut-liver signaling alongside its other benefits.

1
PubMed Central. The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021
2
PubMed Central. Diabetes and liver cirrhosis: shared pathways and clinical implications – a narrative review
3
PubMed Central. Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions
4
PubMed Central. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets
5
PubMed. Diabetes mellitus and the progression of non-alcoholic fatty liver disease to decompensated cirrhosis: a retrospective cohort study
6
PubMed Central. Effect of common genetic variants on the risk of cirrhosis in non-alcoholic fatty liver disease during 20 years of follow-up
7
PubMed. Meta-Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
8
The Lancet. Cirrhosis
9
PubMed Central. Pathophysiology of portal hypertension
10
PubMed Central. Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges
11
Clinical Gastroenterology and Hepatology. Cirrhosis Secondary to NASH: Causes, Symptoms, and Treatment
12
PubMed Central. Nonalcoholic Fatty Liver Disease and Obesity Treatment
13
PubMed. A low-energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis
14
PubMed Central. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH
15
PubMed. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
16
PubMed. Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
17
PubMed. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
18
PubMed Central. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
19
PubMed. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
20
Journal of Hepatology. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
21
PubMed Central. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management
22
American Heart Journal Plus: Cardiology Research and Practice. Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
23
PubMed Central. Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases
24
Journal of Clinical and Translational Hepatology. Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis
25
PubMed Central. Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
26
PubMed Central. The Progression and Natural History of Pediatric Nonalcoholic Fatty Liver Disease
27
PubMed. Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition
28
PubMed Central. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms